Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BARDA Lays Out Vision For Next Pandemic: Vaccines For The US Within 130 Days

Executive Summary

Federal agency seeks dialogue with industry on how to enable surge capacity for pandemic vaccines without cutting back on other production.One key factor: workforce development.

You may also be interested in...



As Emergent Partnership Dissolves, BARDA Looks To Revamp Post-COVID Pandemic Preparedness

BARDA terminates CIADM contract in wake of vaccine cross-contamination incident, begins discussion with industry about next steps for rapid pandemic response capabilities.

Workforce Of The Future Initiative Aims To Close Skills Gap In Biopharmaceutical Industry

The biopharmaceutical industry is expanding its presence on college campuses to address a shortage of workers proficient in advanced manufacturing, cell and gene therapies and combination products. Executives say that not having enough of these skilled workers keeps them up at night.

As Saline Shortages Persist, Providers Pin Hopes On Feds Demanding Backup Manufacturing Capacity

As market forces, seasonal flu and extreme weather cause US shortages of intravenous saline solutions to persist, providers writing in NEJM are heartened by idea that federal Homeland Security Department could step in to require manufacturing redundancies. Will industry solve the problem before it becomes a matter of national security?

Topics

Related Companies

UsernamePublicRestriction

Register

PS145272

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel